Last reviewed · How we verify
Oxaliplatin, Irinotecan, Bevacizumab, Docetaxel
Oxaliplatin, Irinotecan, Bevacizumab, Docetaxel is a Small molecule drug developed by Arbeitsgemeinschaft medikamentoese Tumortherapie. It is currently in Phase 2 development.
At a glance
| Generic name | Oxaliplatin, Irinotecan, Bevacizumab, Docetaxel |
|---|---|
| Sponsor | Arbeitsgemeinschaft medikamentoese Tumortherapie |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors (PHASE1, PHASE2)
- Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (PHASE1)
- Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients (PHASE2)
- Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oxaliplatin, Irinotecan, Bevacizumab, Docetaxel CI brief — competitive landscape report
- Oxaliplatin, Irinotecan, Bevacizumab, Docetaxel updates RSS · CI watch RSS
- Arbeitsgemeinschaft medikamentoese Tumortherapie portfolio CI
Frequently asked questions about Oxaliplatin, Irinotecan, Bevacizumab, Docetaxel
What is Oxaliplatin, Irinotecan, Bevacizumab, Docetaxel?
Oxaliplatin, Irinotecan, Bevacizumab, Docetaxel is a Small molecule drug developed by Arbeitsgemeinschaft medikamentoese Tumortherapie.
Who makes Oxaliplatin, Irinotecan, Bevacizumab, Docetaxel?
Oxaliplatin, Irinotecan, Bevacizumab, Docetaxel is developed by Arbeitsgemeinschaft medikamentoese Tumortherapie (see full Arbeitsgemeinschaft medikamentoese Tumortherapie pipeline at /company/arbeitsgemeinschaft-medikamentoese-tumortherapie).
What development phase is Oxaliplatin, Irinotecan, Bevacizumab, Docetaxel in?
Oxaliplatin, Irinotecan, Bevacizumab, Docetaxel is in Phase 2.